Lisa D. Eli

2.0k total citations
26 papers, 549 citations indexed

About

Lisa D. Eli is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Lisa D. Eli has authored 26 papers receiving a total of 549 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Lisa D. Eli's work include HER2/EGFR in Cancer Research (18 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Advanced Breast Cancer Therapies (9 papers). Lisa D. Eli is often cited by papers focused on HER2/EGFR in Cancer Research (18 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Advanced Breast Cancer Therapies (9 papers). Lisa D. Eli collaborates with scholars based in United States, Spain and Ireland. Lisa D. Eli's co-authors include Nancy L. Maas, Jaime López-Mosqueda, James Wohlschlegel, Zophonı́as O. Jónsson, David P. Toczyski, Alshad S. Lalani, John Crown, Denis M. Collins, Neil T. Conlon and Laurie J. Goodman and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Lisa D. Eli

25 papers receiving 544 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lisa D. Eli United States	12	318	299	147	126	74	26	549
Roza Zandi Denmark	7	264 0.8×	324 1.1×	62 0.4×	91 0.7×	50 0.7×	9	540
Monica Red Brewer United States	7	389 1.2×	361 1.2×	198 1.3×	222 1.8×	30 0.4×	12	630
Neha Luthar United States	6	292 0.9×	236 0.8×	75 0.5×	139 1.1×	37 0.5×	6	525
J. Baselga Spain	10	399 1.3×	312 1.0×	98 0.7×	139 1.1×	32 0.4×	25	649
Marcia R. Campbell United States	9	343 1.1×	255 0.9×	210 1.4×	103 0.8×	14 0.2×	10	512
S. Edgerton United States	6	292 0.9×	269 0.9×	152 1.0×	49 0.4×	40 0.5×	8	560
Elza Friedländer Hungary	7	370 1.2×	223 0.7×	293 2.0×	47 0.4×	37 0.5×	7	530
Nikia A. Laurie United States	10	485 1.5×	455 1.5×	45 0.3×	59 0.5×	38 0.5×	12	756
Patricia Villagrasa Spain	10	293 0.9×	398 1.3×	33 0.2×	106 0.8×	65 0.9×	56	631
Jennifer A. Lacap France	8	418 1.3×	146 0.5×	149 1.0×	227 1.8×	47 0.6×	12	558

Countries citing papers authored by Lisa D. Eli

Since Specialization

Citations

This map shows the geographic impact of Lisa D. Eli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa D. Eli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa D. Eli more than expected).

Fields of papers citing papers by Lisa D. Eli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa D. Eli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa D. Eli. The network helps show where Lisa D. Eli may publish in the future.

Co-authorship network of co-authors of Lisa D. Eli

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa D. Eli. A scholar is included among the top collaborators of Lisa D. Eli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa D. Eli. Lisa D. Eli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Conlon, Neil T., Sandra Roche, Laura Breen, et al.. (2024). Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo. Translational Oncology. 49. 102073–102073. 2 indexed citations

Goldman, Jonathan W., Christophe Dooms, Komal Jhaveri, et al.. (2024). Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial. Clinical Lung Cancer. 26(3). 191–200.e1. 1 indexed citations

Owonikoko, Taofeek K., Alberto Chiappori, Ryan D. Gentzler, et al.. (2024). Alisertib in patients with extensive-stage small-cell lung cancer: The phase 2 ALISCA-Lung1 study.. Journal of Clinical Oncology. 42(16_suppl). TPS8128–TPS8128. 1 indexed citations

Friedman, Claire F., Anishka D'souza, Diana Bello Roufai, et al.. (2024). Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial. Gynecologic Oncology. 181. 162–169. 15 indexed citations

Abou‐Alfa, Ghassan K., Tim Meyer, Richard Kinh Gian, et al.. (2024). Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma. Liver Cancer. 14(1). 1–10. 1 indexed citations

Jhaveri, Komal, Sara A. Hurvitz, Adam Brufsky, et al.. (2024). Efficacy and genomic analysis of HER2-mutant, metastatic triple-negative breast cancer treated with neratinib alone or in combination with trastuzumab in the phase 2 SUMMIT basket trial.. Journal of Clinical Oncology. 42(16_suppl). 1094–1094. 1 indexed citations

Marín, Arnaldo, Hima Patel, Hiroaki Akamatsu, et al.. (2023). Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer. Cancer Research. 83(18). 3145–3158. 14 indexed citations

Eli, Lisa D. & Shyam M. Kavuri. (2022). Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer. Cancer Drug Resistance. 5(4). 873–881. 7 indexed citations

Conlon, Neil T., Naomi Walsh, Irmina Diala, et al.. (2022). Abstract P2-13-36: Comparative time course analysis of the effects of neratinib, lapatinib and tucatinib in an in vitro HER2+ breast cancer model. Cancer Research. 82(4_Supplement). P2–13. 1 indexed citations

10.

Jhaveri, Komal, Haeseong Park, James Waisman, et al.. (2022). Abstract GS4-10: Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial. Cancer Research. 82(4_Supplement). GS4–10. 7 indexed citations

11.

Akamatsu, Hiroaki, Dan Ye, Dhivya R. Sudhan, et al.. (2022). Abstract P4-01-02: A spectrum of secondary mutations in HER2 augment breast cancer cell growth and reduce neratinib sensitivity in HER2-mutant breast cancer. Cancer Research. 82(4_Supplement). P4–1.

12.

Saura, Cristina, Judit Matito, Mafalda Oliveira, et al.. (2021). Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. Clinical Cancer Research. 27(21). 5818–5827. 15 indexed citations

13.

Conlon, Neil T., Suzanne J.C. van Gerwen, Guido J.R. Zaman, et al.. (2021). Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors. British Journal of Cancer. 124(7). 1249–1259. 39 indexed citations

14.

Goldman, Jonathan W., Santiago Viteri, Amit Mahipal, et al.. (2021). Neratinib efficacy in a subgroup of patients with EGFR exon 18-mutant non-small cell lung cancer (NSCLC) and central nervous system (CNS) involvement: Findings from the SUMMIT basket trial.. Journal of Clinical Oncology. 39(15_suppl). 9068–9068. 4 indexed citations

15.

Lee, Jangsoon, Toshiaki Iwase, Alshad S. Lalani, et al.. (2021). PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening. Biomedicines. 9(7). 740–740. 11 indexed citations

16.

Chumsri, Saranya, Jodi Weidler, Siraj M. Ali, et al.. (2015). Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring anERBB2S310F Mutation. Journal of the National Comprehensive Cancer Network. 13(9). 1066–1070. 25 indexed citations

17.

Garrett, Joan T., Cammie R. Sutton, Richard Kurupi, et al.. (2013). Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers. Cancer Research. 73(19). 6013–6023. 72 indexed citations

18.

Chenna, Ahmed, Weidong Huang, Gayle Marshall, et al.. (2013). Abstract 3029: Profiling HER3/ErbB3 activation in formalin-fixed, paraffin-embedded (FFPE) breast tumor samples that express high and low HER2/ErbB2 levels using proximity-based immunoassays.. Cancer Research. 73(8_Supplement). 3029–3029. 3 indexed citations

19.

Eli, Lisa D., et al.. (2011). Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action. Breast Cancer Research. 13(2). R44–R44. 69 indexed citations

20.

López-Mosqueda, Jaime, Nancy L. Maas, Zophonı́as O. Jónsson, et al.. (2010). Damage-induced phosphorylation of Sld3 is important to block late origin firing. Nature. 467(7314). 479–483. 147 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact